Pharma Business review is using cookies

ContinueLearn More
Close
 

All articles by  

OvaScience, Millendo Therapeutics agree to merge

Millendo is engaged in the development of novel treatments for orphan endocrine diseases. The combined company will further advance Millendo’s pipeline of transformative treatments for orphan endocrine diseases.